Nationwide Fund Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-204,103
Closed -$63.9M 263
2017
Q3
$63.9M Sell
204,103
-11,818
-5% -$3.5M 0.25% 54
2017
Q2
$58.6M Sell
215,921
-26,524
-11% -$7.01M 0.24% 56
2017
Q1
$66.3M Sell
242,445
-21,187
-8% -$5.99M 0.27% 45
2016
Q4
$74.8M Sell
263,632
-4,372
-2% -$1.3M 0.31% 39
2016
Q3
$83.9M Sell
268,004
-19,393
-7% -$5.74M 0.35% 33
2016
Q2
$69.5M Buy
287,397
+98,849
+52% +$26.1M 0.3% 45
2016
Q1
$44.3M Sell
188,548
-17,307
-8% -$4.57M 0.19% 95
2015
Q4
$63.1M Sell
205,855
-116,726
-36% -$33.5M 0.27% 55
2015
Q3
$94.1M Sell
322,581
-33,248
-9% -$11M 0.42% 29
2015
Q2
$144M Buy
355,829
+20,721
+6% +$8.32M 0.59% 13
2015
Q1
$141M Buy
335,108
+34,944
+12% +$13.8M 0.57% 13
2014
Q4
$102M Sell
300,164
-17,301
-5% -$5.6M 0.44% 25
2014
Q3
$105M Buy
317,465
+25,878
+9% +$8.53M 0.44% 26
2014
Q2
$91.9M Sell
291,587
-22,647
-7% -$6.82M 0.37% 32
2014
Q1
$96.1M Sell
314,234
-33,808
-10% -$10.7M 0.44% 25
2013
Q4
$97.4M Sell
348,042
-9,763
-3% -$2.53M 0.41% 26
2013
Q3
$86.1M Buy
357,805
+44,644
+14% +$9.99M 0.39% 30
2013
Q2
$67.4M Buy
+313,161
New +$66.9M 0.36% 39

Other funds holding BIIB

Nationwide Fund Advisors's BIIB Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Biogen (BIIB) in Q4 2017, closing a stake of 204,103 shares — an estimated $63.9M sold.

Nationwide Fund Advisors first reported a position in BIIB in Q2 2013 and held it in 18 quarters. The position peaked at $144M in Q2 2015. 1,122 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Biogen position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 204,103 Biogen shares in Q4 2017, an estimated $63.9M.
  • Nationwide Fund Advisors first reported a position in Biogen in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Biogen position peaked at $144M in Q2 2015.
  • 1,122 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.